Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
As skin ages, it becomes thinner and more easily damaged. Intensifying this effect is the decreasing ability of skin to heal itself as a person ages. Among other things, skin ageing is noted by a decrease in volume and elasticity. There are many internal and external causes to skin ageing. For example, ageing skin receives less blood flow and lower glandular activity. A validated comprehensive grading scale has categorized the clinical findings of skin ageing as laxity (sagging), rhytids (wrinkles), and the various facets of photoageing, including erythema (redness), and telangiectasia, dyspigmentation (brown discolouration), solar elastosis (yellowing), keratoses (abnormal growths) and poor texture. Cortisol causes degradation of collagen, accelerating skin ageing. Anti-ageing supplements are used to treat skin ageing.
At first sight this appears to offer a means of obtaining the standard molar enthalpy of the reaction by studying the variation of K with temperature. In practice, however, the method is unreliable because error propagation almost always gives very large errors on the values calculated in this way.
18 April to 31 December Operation Dan Thang 69 was conducted by the ARVN 22nd Division in Bình Định Province. The operation resulted in 507 PAVN/VC killed. Operation Dan Tien 33D was conducted by the ARVN 23rd Division in Quang Duc Province. The operation resulted in 746 PAVN/VC killed.
A seminal work of traditional Chinese medicine was the Huangdi neijing (Yellow Emperor's Inner Canon) compiled between the 3rd and 2nd centuries BC (i.e. originating in the Warring States period), which viewed the human body, its organs and tissues through the lens of the metaphysical five phases and yin and yang, and stated a belief in two circulatory channels of qi vital energy. In surgery, Han dynasty era Chinese texts offered practical advice for certain procedures such as clinical lancing of abscesses. The first known physician in China to describe the use anesthesia for patients undergoing surgery was the Eastern Han physician Hua Tuo (d. 208 AD), who utilized his knowledge of Chinese herbology based in the Huangdi neijing to create an ointment that healed surgical wounds within a month. One of his surgical procedures was the removal of a dead fetus from the womb of a woman whom he diagnosed and cured of her ailments.
Sources: en.wikipedia.org
To ensure highly anisotropic, yet predictable solidification behavior within the SSZ, dynamic freezing patterns are preferred. Using dynamic freezing, the velocity of the solidification front, and, therefore, the ice crystal size, can be controlled with a changing temperature gradient. The increasing thermal gradient counters the effect of the growing thermal buffer imposed by the growing ice front. It has been shown that a linearly decreasing temperature on one side of a freeze-cast will result in near-constant solidification velocity, yielding ice crystals with an almost constant thickness along the SSZ of an entire sample. However, as pointed out by Waschkies et al. even with constant solidification velocity, the thickness of the ice crystals does increase slightly over the course of freezing. In contrast to that, Flauder et al. demonstrated that an exponential change of the temperature at the cooling plate leads to a constant ice crystal thickness within the complete SSZ, which was attributed to a measurably constant ice-front velocity in a distinct study. This approach enables a prediction of the ice-front velocity from the thermal parameters of the suspension. Consequently, if the exact relationship between the pore diameter and ice-front velocity is known, an exact control over the pore diameter can be achieved.
==== MeSH D13.695.827 – ribonucleotides ==== MeSH D13.695.827.068 – adenine nucleotides MeSH D13.695.827.068.124 – adenosine diphosphate MeSH D13.695.827.068.124.070 – adenosine diphosphate sugars MeSH D13.695.827.068.124.070.075 – adenosine diphosphate glucose MeSH D13.695.827.068.124.070.125 – adenosine diphosphate ribose MeSH D13.695.827.068.124.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.827.068.124.070.125.195 – cyclic adp-ribose MeSH D13.695.827.068.180 – adenosine monophosphate MeSH D13.695.827.068.180.080 – adenosine phosphosulfate MeSH D13.695.827.068.236 – adenosine triphosphate MeSH D13.695.827.068.236.050 – adenylyl imidodiphosphate MeSH D13.695.827.068.236.250 – ethenoadenosine triphosphate MeSH D13.695.827.068.382 – coenzyme a MeSH D13.695.827.068.382.300 – acyl coenzyme a MeSH D13.695.827.068.382.300.020 – acetyl coenzyme a MeSH D13.695.827.068.382.300.500 – malonyl coenzyme a MeSH D13.695.827.068.382.300.700 – palmitoyl coenzyme a MeSH D13.695.827.068.395 – cyclic amp MeSH D13.695.827.068.395.225 – 8-bromo cyclic adenosine monophosphate MeSH D13.695.827.068.395.250 – bucladesine MeSH D13.695.827.068.506 – flavin-adenine dinucleotide MeSH D13.695.827.068.694 – nad MeSH D13.695.827.068.749 – nadp MeSH D13.695.827.068.850 – phosphoadenosine phosphosulfate MeSH D13.695.827.232 – cytosine nucleotides MeSH D13.695.827.232.115 – cyclic cmp MeSH D13.695.827.232.150 – cytidine diphosphate MeSH D13.695.827.232.150.180 – cytidine diphosphate choline MeSH D13.695.827.232.150.210 – cytidine diphosphate diglycerides MeSH D13.695.827.232.370 – cytidine monophosphate MeSH D13.695.827.232.370.250 – cytidine monophosphate n-acetylneuraminic acid MeSH D13.695.827.232.400 – cytidine triphosphate MeSH D13.695.827.349 – flavin mononucleotide MeSH D13.695.827.426 – guanine nucleotides MeSH D13.695.827.426.160 – cyclic gmp MeSH D13.695.827.426.160.325 – dibutyryl cyclic gmp MeSH D13.695.827.426.340 – guanosine diphosphate MeSH D13.695.827.426.340.350 – guanosine diphosphate sugars MeSH D13.695.827.426.340.350.400 – guanosine diphosphate fucose MeSH D13.695.827.426.340.350.500 – guanosine diphosphate mannose MeSH D13.695.827.426.440 – guanosine pentaphosphate MeSH D13.695.827.426.480 – guanosine tetraphosphate MeSH D13.695.827.426.504 – guanosine triphosphate MeSH D13.695.827.426.504.380 – guanosine 5'-o-(3-thiotriphosphate) MeSH D13.695.827.426.504.400 – guanylyl imidodiphosphate MeSH D13.695.827.426.525 – 5'-guanylic acid MeSH D13.695.827.426.700 – rna caps MeSH D13.695.827.426.700.710 – rna cap analogs MeSH D13.695.827.519 – inosine nucleotides MeSH D13.695.827.519.300 – cyclic imp MeSH D13.695.827.519.400 – inosine diphosphate MeSH D13.695.827.519.500 – inosine monophosphate MeSH D13.695.827.519.800 – inosine triphosphate MeSH D13.695.827.648 – nicotinamide mononucleotide MeSH D13.695.827.708 – nucleoside diphosphate sugars MeSH D13.695.827.708.070 – adenosine diphosphate sugars MeSH D13.695.827.708.070.075 – adenosine diphosphate glucose MeSH D13.695.827.708.070.125 – adenosine diphosphate ribose MeSH D13.695.827.708.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.827.708.070.125.195 – cyclic adp-ribose MeSH D13.695.827.708.070.125.600 – poly adenosine diphosphate ribose MeSH D13.695.827.708.260 – cytidine diphosphate diglycerides MeSH D13.695.827.708.400 – guanosine diphosphate sugars MeSH D13.695.827.708.400.410 – guanosine diphosphate fucose MeSH D13.695.827.708.400.500 – guanosine diphosphate mannose MeSH D13.695.827.708.727 – uridine diphosphate sugars MeSH D13.695.827.708.727.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.827.708.727.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.827.708.727.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.827.708.727.300 – uridine diphosphate galactose MeSH D13.695.827.708.727.350 – uridine diphosphate glucose MeSH D13.695.827.708.727.375 – uridine diphosphate glucuronic acid MeSH D13.695.827.708.727.800 – uridine diphosphate xylose MeSH D13.695.827.919 – uracil nucleotides MeSH D13.695.827.919.600 – uridine diphosphate MeSH D13.695.827.919.600.677 – uridine diphosphate sugars MeSH D13.695.827.919.600.677.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.827.919.600.677.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.827.919.600.677.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.827.919.600.677.300 – uridine diphosphate galactose MeSH D13.695.827.919.600.677.350 – uridine diphosphate glucose MeSH D13.695.827.919.600.677.375 – uridine diphosphate glucuronic acid MeSH D13.695.827.919.600.677.800 – uridine diphosphate xylose MeSH D13.695.827.919.877 – uridine monophosphate MeSH D13.695.827.919.950 – uridine triphosphate
== Long-term potentiation == Calcium/ calmodulin dependent protein kinase II is also heavily implicated in long-term potentiation (LTP) – the molecular process of strengthening active synapses that is thought to underlie the processes of memory. It is involved in many aspects of this process. LTP is initiated when the NMDA receptors are in a local environment with a voltage potential high enough to displace the positively-charged Mg2+ ion from the channel pore. As a result of the channel being unblocked, Ca2+ ions are able to enter into the postsynaptic neuron through the NMDA receptor channel. This Ca2+ influx activates CaMKII. It has been shown that there is an increase in CaMKII activity directly in the post synaptic density of dendrites after LTP induction, suggesting that activation is a direct result of stimulation.
Sources: en.wikipedia.org
=== Detection === A procedure of retrospective detection of Novichok type poisons in victim's tissues was proposed in 2021-2. This method is a modification of the procedure that was developed earlier for identification of sarin poisoning. This method capitalizes on the fact that poisoning by organic phosphonates occurs via phosphonylation of the hydroxy group of serine in the active site of cholinesterases, and that severe poisoning occurs when a major part of these enzymes are inactivated. The concentration of butyryl cholinesterase (HuBuChE) in human plasma is normally about 80 nM. That makes it a good source of adducts that can be subjected to analysis. The procedure consists of three steps (see the Figure A). First, HuBuChE is obtained from the victim's plasma. Second, the enzyme is subjected to pepsin proteolysis. Third, the peptide mixture obtained is subjected to LC-MSMS analysis. If no poisoning took place, the peptide mixture contains a non-modified nonapeptide FGESAGAAS. However, cholinesterases are inactivated due to a chemical reaction with Novichok type nerve agent, the modified nonapeptide is be detected, and its exact (high resolution) mass (along with the mass of the secondary ion produced during collision induced dissociation) allows unambiguous identification of the fact of poisoning and the exact structure of the poison. Thus, the example at Figure A shows the masses of the primary and secondary ions obtained from the plasma of the victim poisoned by A-230. If a victim is poisoned by other Novichok type agents, the masses are different.
Hormones during pregnancy are the result of an intricate interaction between hormones generated by different glands and organs. The primary hormones involved comprise human chorionic gonadotropin (hCG), progesterone, estrogen, human placental lactogen (hPL), and oxytocin. Hormones are synthesized in certain organs, including the ovaries, placenta, and pituitary gland. These hormones have essential functions in pregnancy test, maintaining the uterine lining, fetal development, preventing premature labor, and the initiation and support of labor. Subsequently, the hormones are stored and released into the circulation to be conveyed to the specific cells they are intended for. Once they reach the target cells, they are recognized by associated cell membrane or intracellular receptor proteins, leading to a cellular response. There are disorders related to hormonal imbalances, such as breast cancer, hyperrelaxinemia and Polycystic Ovary Syndrome (PCOS), having a significant influence on reproductive health.
=== January === 1 January – A visit by Thor the Walrus to Scarborough harbour, North Yorkshire overnight on New Year's Eve results in the town's New Year fireworks celebrations being cancelled to let the walrus rest for his journey to the Arctic. He was previously spotted at Pagham Harbour, Calshot, Hampshire in December 2022. 2 January – Thor the Walrus makes an appearance in Blyth, Northumberland. 7 January – Prime Minister Rishi Sunak holds talks with health leaders in England to discuss pressures facing the National Health Service. 8 January – The government confirms plans to ban single-use items such as plastic cutlery, plates, and trays in England, with the ban subsequently announced to take effect from October. 13 January Dennis McGrory, aged 75, is sentenced to life imprisonment for the 1975 murder of 15-year-old Jacqueline Montgomery following a trial at Huntingdon Crown Court. His conviction is the oldest murder case in England and Wales to involve the rule of double jeopardy. Following a trial at Hove Crown Court, Mark Brown, 41, of St Leonards-on-Sea, East Sussex, is given two life sentences for the 2021 murders of Alexandra Morgan and Leah Ware. 14 January – Four women and two children are injured in a drive-by mass shooting close to a Catholic church in Euston Road, Euston, Central London. A 22-year-old man is arrested two days later on suspicion of attempted murder.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.